[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Fennec Pharmaceuticals Inc (FENC)

Fennec Pharmaceuticals Inc (FENC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 421,748
  • Shares Outstanding, K 35,058
  • Annual Sales, $ 44,640 K
  • Annual Income, $ -9,740 K
  • EBIT $ -1 M
  • EBITDA $ -1 M
  • 60-Month Beta 1.10
  • Price/Sales 9.70
  • Price/Cash Flow N/A
  • Price/Book 10.19

Options Overview Details

View History
  • Implied Volatility 183.28% (+28.37%)
  • Historical Volatility 68.47%
  • IV Percentile 24%
  • IV Rank 16.78%
  • IV High 674.76% on 03/18/26
  • IV Low 84.15% on 10/30/25
  • Expected Move (DTE 16) 1.61 (13.37%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 65
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 225
  • Open Int (30-Day) 827
  • Expected Range 10.41 to 13.63

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $0.10
  • Number of Estimates 4
  • High Estimate $0.14
  • Low Estimate $0.06
  • Prior Year $-0.02
  • Growth Rate Est. (year over year) +600.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.47 +26.72%
on 08/03/26
13.25 -9.43%
on 08/12/26
+2.43 (+25.39%)
since 07/31/26
3-Month
8.52 +40.93%
on 06/11/26
13.25 -9.43%
on 08/12/26
+2.02 (+20.24%)
since 06/02/26
52-Week
5.65 +112.39%
on 04/13/26
13.25 -9.43%
on 08/12/26
+3.09 (+34.68%)
since 09/02/25

Most Recent Stories

More News
Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

~ 2026 Second Quarter Net Product Sales of $17.1 Million, Up 78% Year over Year ~ ~ 2026 Second Quarter Non-GAAP Adjusted EBITDA of $2.8 Million ~ ~...

FRX.TO : 17.00 (+9.75%)
FENC : 12.10 (+0.58%)
Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

~ 2026 Second Quarter Net Product Sales of $17.1 Million, Up 78% Year over Year ~ ~ 2026 Second Quarter Non-GAAP Adjusted EBITDA of $2.8 Million ~ ~ Record PEDMARK ® Demand Carried...

FRX.TO : 17.00 (+9.75%)
FENC : 12.10 (+0.58%)
Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026

RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company...

FRX.TO : 17.00 (+9.75%)
FENC : 12.10 (+0.58%)
Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026

RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company...

FRX.TO : 17.00 (+9.75%)
FENC : 12.10 (+0.58%)
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

RESEARCH TRIANGLE PARK, N.C., June 22, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a...

FRX.TO : 17.00 (+9.75%)
FENC : 12.10 (+0.58%)
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

RESEARCH TRIANGLE PARK, N.C., June 22, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced...

FRX.TO : 17.00 (+9.75%)
FENC : 12.10 (+0.58%)
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

RESEARCH TRIANGLE PARK, N.C., June 15, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced...

FRX.TO : 17.00 (+9.75%)
FENC : 12.10 (+0.58%)
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

RESEARCH TRIANGLE PARK, N.C., June 15, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a...

FRX.TO : 17.00 (+9.75%)
FENC : 12.10 (+0.58%)
Fennec Announces Results of Annual Meeting

RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy...

FRX.TO : 17.00 (+9.75%)
FENC : 12.10 (+0.58%)
Fennec Announces Results of Annual Meeting

RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that...

FRX.TO : 17.00 (+9.75%)
FENC : 12.10 (+0.58%)

Business Summary

Fennec Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients. The Company's products include Eniluracil and Sodium Thiosulfate (STS). Fennec Pharmaceuticals Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 12.88
2nd Resistance Point 12.65
1st Resistance Point 12.34
Last Price 12.10
1st Support Level 11.80
2nd Support Level 11.57
3rd Support Level 11.26

See More

52-Week High 13.25
Last Price 12.10
Fibonacci 61.8% 10.35
Fibonacci 50% 9.45
Fibonacci 38.2% 8.55
52-Week Low 5.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.